- Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study
- Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
- Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor "no longer observed" following BriaCell treatment
BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.